Inscripta, Inc. Competitors

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Synthego is a CRISPR solutions provider that enables the acceleration of life science research and development in the pursuit of improved human health. Synthego is a pioneering force in the biotechnology industry, dedicated to advancing the frontiers of CRISPR cell and gene therapies through cutting-edge CRISPR technology and expertise. Our mission is to provide unparalleled access to best-in-class CRISPR solutions at scale, empowering agility in life science research and development from discovery through clinical trials. From streamlined approaches to licensing through full technical and regulatory support from our industry-leading experts, Synthego is enabling greater access to CRISPR technology driving to improved outcomes in patient therapeutic treatments. At Synthego, our values define who we are and how we work together to shape the future of science. Ingenuity drives us to innovate and solve complex challenges in groundbreaking ways. Collaboration fuels our success, as we believe the best ideas come from diverse perspectives working together. Kindness shapes our workplace culture, fostering mutual respect and care for one another. Empowerment inspires every team member to take initiative, grow, and make meaningful contributions. Integrity forms the foundation of everything we do, ensuring trust, transparency, and excellence guide our actions. We believe that fostering an environment of belonging is essential to driving innovation and collaboration. Through our Diversity Network Association (DNA), we actively amplify diverse voices, champion equity, and create spaces where inclusivity thrives. These principles are not just policies or initiatives; they’re integrated into our DNA and guide how we work together every day. By weaving diversity, equity, and inclusion into the fabric of our identity, we strengthen our team, inspire new ideas, and ensure everyone can contribute meaningfully to shaping the future of science.